Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Relapse Prevention in Recurrent Depressive Disorder (KINDRED)
NCT02661061Phase 1Terminated
- Sponsor
- St Patrick's Mental Health Services
- Start
- Dec 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketamine in major depressive disorder (MDD), sponsored by St Patrick's Mental Health Services. Primary endpoint: Completion Rate for Randomised Treatment Phase at 2 years. Started Dec 2015; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02661061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661061.